<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01953744</url>
  </required_header>
  <id_info>
    <org_study_id>FlucoLBrBaMa</org_study_id>
    <nct_id>NCT01953744</nct_id>
  </id_info>
  <brief_title>High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus</brief_title>
  <official_title>Phase 3 Randomized Trial Comparing Fluconazole to Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Caused by L. Braziliensis and L. Guyanensis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitário Professor Edgard Santos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federal University of Bahia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitário Professor Edgard Santos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the therapeutic response to fluconazole in patients
      with cutaneous leishmaniasis caused by and L.(V.)guyanensis and L.(V.) braziliensis.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low cure rate in the study (fluconazole) group
  </why_stopped>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cure rate or complete cicatrization of the ulcer.</measure>
    <time_frame>6 months</time_frame>
    <description>All lesions will be categorized as either active or healed (cured) at follow-up visits. Only lesions with complete re-epithelialization, without raised borders, infiltrations or crusts will be considered healed. Evaluation of the lesions will be performed by 2 clinicians who will be unaware of the group assignment of all patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Initial cure rate or complete cicatrization of the ulcer</measure>
    <time_frame>2 months</time_frame>
    <description>All lesions will be categorized as either active or healed (cured) at follow-up visits. Only lesions with complete re-epithelialization, without raised borders, infiltrations or crusts will be considered healed. Evaluation of the lesions will be performed by 2 clinicians who will be unaware of the group assignment of all patients.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Cutaneous Leishmaniasis</condition>
  <arm_group>
    <arm_group_label>Fluconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluconazole will be administered by oral route at 6-8mg/kg/day during 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meglumine Antimoniate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Meglumine Antimoniate will be administered by intravenous route at 20mg/kg/day during 20 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <description>Fluconazole is presented in 150mg capsules and will be administered by oral route at a dosage of 6-8mg/kg/day during 28 days.</description>
    <arm_group_label>Fluconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meglumine Antimoniate</intervention_name>
    <description>Meglumine Antimoniate will be administered as the standard treatment for cutaneous leishmaniasis by intravenous route at a dosage of 20mg/kg/day, during 20 days.</description>
    <arm_group_label>Meglumine Antimoniate</arm_group_label>
    <other_name>Glucantime</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed (untreated) cutaneous leishmaniasis with localized lesions and a
             positive culture or diagnosed by polymerase chain reaction (PCR) methods or by
             intradermal skin testing (Montenegro test).

          -  Number of lesions: 1 to 3 ulcerative lesions.

          -  Lesion´s diameter: 1 to 5 cm.

          -  Disease duration: up to three months.

        Exclusion Criteria:

          -  Evidence of serious underlying disease (cardiac, renal, hepatic or pulmonary)

          -  Immunodeficiency or antibody to HIV

          -  Any non-compensated or uncontrolled condition, such as active tuberculosis, malignant
             disease, severe malaria, HIV, or other major infectious diseases

          -  Lactation, pregnancy (to be determined by adequate test) or inadequate contraception
             in females of childbearing potential for treatment period plus 2 months

               -  Lack of suitability for the trial:

          -  Negative parasitology (aspirate/biopsy/PCR)or negative Montenegro test

          -  Any history of prior anti-leishmania therapy

          -  Any condition which compromises ability to comply with the study procedures

               -  Administrative reasons:

          -  Lack of ability or willingness to give informed consent (patient and/or parent / legal
             representative)

          -  Anticipated non-availability for study visits/procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paulo Roberto Lima Machado, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bahia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Posto de Saúde de Corte de Pedra</name>
      <address>
        <city>Presidente Tancredo Neves</city>
        <state>Bahia</state>
        <zip>45416000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2013</study_first_submitted>
  <study_first_submitted_qc>September 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2013</study_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitário Professor Edgard Santos</investigator_affiliation>
    <investigator_full_name>Paulo Roberto Lima Machado</investigator_full_name>
    <investigator_title>Associate Researcher</investigator_title>
  </responsible_party>
  <keyword>Fluconazole; Meglumine antimoniate;L.Braziliensis;</keyword>
  <keyword>L.Guyanensis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Meglumine antimoniate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

